Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis

Summary

The primary objective of the study was to evaluate the efficacy and safety of 611 in chinese adults with moderate to severe atopic dermatitis.

Timeline

Start

2022-10-26

Primary completion

2023-07-10

Completion

2023-09-20

Outcome

Met primary endpoint

paper 60.0% of patients in Group A and 48.8% in Group B achieved EASI-75, both significantly higher than the placebo group (15.6%, p < 0.01). PMID 40057938 ↗

Publications

• Zhao Y, Zhang L, Wu L, Duan X, Ji C, Xiao R, Ji M, Liu L, Yang B, Hu G, Feng Y, Zhu J, Li J, Ding Y, Huang H, Zhou Q, Xu Y, Zhang J. Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial. Dermatol Ther (Heidelb). 2025 Apr;15(4):857-867. doi: 10.1007/s13555-025-01368-4. Epub 2025 Mar 9.

Drugs

Indications